{
    "clinical_study": {
        "@rank": "136095", 
        "acronym": "PMNC", 
        "arm_group": [
            {
                "arm_group_label": "Spectra Optia", 
                "arm_group_type": "Other", 
                "description": "Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device."
            }, 
            {
                "arm_group_label": "COBE Spectra", 
                "arm_group_type": "Other", 
                "description": "Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the procedures for the collection PMN cells on\n      Terumo BCT's Spectra Optia\u00ae and COBE\u00ae Spectra Apheresis Systems."
        }, 
        "brief_title": "Evaluation of the Spectra Optia PMN Cell Collection Procedure", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Granulocyte/ Polymorphonuclear Cells", 
        "detailed_description": {
            "textblock": "The purpose of this study is to compare the procedures for the collection of granulocyte/\n      polymorphonuclear (PMN) cells on Terumo BCT's Spectra Optia\u00ae and COBE\u00ae Spectra Apheresis\n      Systems and to establish the non-inferiority of the Spectra Optia Apheresis System with\n      respect to the primary study endpoint, granulocyte/PMN cell collection efficiency."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acceptable health status and vital signs per the AABB blood donation guidelines to\n             permit blood donation, including:\n\n               1. Blood pressure \u2265 90/50 and \u2264 200/120 mmHg,\n\n               2. Pulse > 40 and < 100 beats/min, and\n\n               3. Temperature < 99.5\u00baFahrenheit (F).\n\n          -  Able to read, understand, and sign an English informed consent form.\n\n          -  Age \u2265 18 years.\n\n          -  Weight \u2265 50kg and < 227kg.\n\n          -  Male or non-pregnant, non-nursing female (a negative serum pregnancy test at\n             screening and a negative urine pregnancy test prior to each mobilization).\n\n          -  Acceptable screening laboratory test results prior to the first PMN cell\n             mobilization, including:\n\n               1. WBC count in the range: 3,500-10,800/uL,\n\n               2. Hematocrit in the range: 38-65%,\n\n               3. Platelet count in the range:  150,000-400,000/uL,\n\n               4. Coagulation tests: PT not greater than 1.1 times the upper limit of the local\n                  laboratory reference range; PTT not greater than 1.2 times the upper limit of\n                  the local laboratory reference range,\n\n               5. Serum electrolyte concentrations: potassium in the range 3.6-5.1 mmol/L; calcium\n                  in the range 8.5-10.3 mg/dL,\n\n               6. Serum creatinine not greater than 1.5mg/dL, and\n\n               7. ALT not greater than 1.5 times the upper limit of the local laboratory reference\n                  range. *** Up to two (2) of the above screening laboratory test results may fall\n                  outside of these ranges, if in the judgment of the principal investigator or\n                  designee, they do not constitute a significant risk to the subject.  Any excused\n                  deviations from the above will be listed and summarized with the final\n                  report.***\n\n          -  Adequate dual peripheral venous access to allow collection of granulocytes (PMN\n             cells) and return of remaining cells, platelets and plasma.\n\n          -  If male, willing to use a condom during sexual relations with a female partner of\n             child bearing potential until 48 hours following each G-CSF injection.\n\n          -  If female, willing to use a medically-acceptable contraceptive until 48 hours\n             following each G-CSF injection.\n\n        Exclusion Criteria:\n\n          -  Positive screening for any of the following: HIV, HBV (except isolated HB core Ab\n             reactivity), HCV, HTLV, Syphilis or West Nile Virus.\n\n          -  Currently pregnant or breast-feeding.\n\n          -  Collection or loss of specific volumes of whole blood or blood components during\n             specified timeframes:\n\n               1. more than 550mL of whole blood within the prior 56 days, or\n\n               2. more than 3L of whole blood or 1.5L of red blood cells within the prior 12\n                  months, or\n\n               3. more than 12L of plasma within the prior 12 months, or\n\n               4. a leukapheresis within the prior six weeks, or\n\n               5. a plateletpheresis within the prior 48 hours or two within the prior 7 days or\n                  twenty-four within the last 12 months, or\n\n               6. a plasmapheresis within the prior 48 hours or two within the prior 7 days.\n\n          -  History of congestive heart failure.\n\n          -  History of uncontrolled hypertension (SBP/DBP >200/120 mmHg).\n\n          -  History or suspicion of active, peptic ulcer disease.\n\n          -  History of diabetes mellitus.\n\n          -  History of hematologic malignancy or chronic hematologic disorder.\n\n          -  Family history (parents, siblings, children) of hematologic malignancy.\n\n          -  History of deep vein thrombosis or venous thromboembolism, or bleeding disorder.\n\n          -  History of sickle cell disease or a positive SickleDex screen.\n\n          -  History of iritis or episcleritis.\n\n          -  History of autoimmune condition or disorder, unless approved by principal\n             investigator.\n\n          -  Presence of psychological traits, or physiological or medical conditions that, in the\n             opinion of the investigator, would make the subject unlikely to tolerate the\n             procedures or complete the study.\n\n          -  History of use/anticipated need for lithium.\n\n          -  Received a G-CSF injection in the prior 4 months.\n\n          -  Known hypersensitivity to ethylene oxide.\n\n          -  Known hypersensitivity to G-CSF or hypersensitivity to any E. coli-derived products.\n\n          -  Known hypersensitivity to HES or corn.\n\n          -  Concurrent participation in another clinical trial or participation in a clinical\n             trial within the past 30 days.\n\n          -  Subject is being treated with calcium channel blockers and/or antiepileptic\n             medications.   Note:  This applies only to Subjects at Bonfils Blood Center whose\n             collected product will undergo neutrophil function testing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805180", 
            "org_study_id": "CTS-5010"
        }, 
        "intervention": [
            {
                "arm_group_label": "COBE Spectra", 
                "description": "In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.", 
                "intervention_name": "Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Spectra Optia", 
                "description": "In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.", 
                "intervention_name": "Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80230"
                    }, 
                    "name": "Bonfils Blood Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267-0055"
                    }, 
                    "name": "Hoxworth Blood Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53233"
                    }, 
                    "name": "Blood Centers of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Controlled Evaluation of the Spectra Optia\u00ae Apheresis System's Granulocyte / Polymorphonuclear (PMN) Cell Collection Procedure", 
        "overall_official": {
            "affiliation": "Terumo BCT", 
            "last_name": "Raymond Goodrich, Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the granulocyte/PMN cell collection efficiency (CE) associated with the Granulocyte (PMN) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems.", 
            "measure": "Granulocyte/PMN cell collection efficiency", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805180"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison of collection efficiencies associated with the Granulocyte Cell Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems for white blood cells and platelets. White Blood Cell (WBC) CE will be calculated using total WBC concentrations/counts obtained on an automated hematology analyzer. Platelet (PLT) CE will likewise be calculated using platelet concentrations/counts from an automated hematology analyzer.\nCharacterization of the collected blood product, including 1) Total PMN cell yield and PMN cell yield per liter blood processed 2) PMN cell viability and, in a subset of collections, PMN cell functionality. 3) Red blood cell (RBC) contamination. 4) Product volume.", 
                "measure": "Performance", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Procedure time.\nNumber of operator adjustments aimed at establishing and maintaining the plasma/ cellular interface:  namely, on Spectra Optia, the adjustment of collection preference and, on COBE Spectra, the adjustment of the plasma pump flow rate.\nDevice malfunctions.", 
                "measure": "Usability/assessment of system operation", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Serious adverse events (SAEs) and unanticipated (serious) adverse device/procedure- related events (UADEs), adverse events (AEs).\nComplete Blood Count with differential white cell count (CBCD).\nVital signs (temperature, heart rate, blood pressure).", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "source": "Terumo BCT", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Terumo BCT", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}